Objective： The aim of our study was to explore the inhibitory effect of Tagalsin on murine transplanted tumour and its anti-tumour mechanisms. Methods： Animal models were established by transplanting H22 hepatoma ce...Objective： The aim of our study was to explore the inhibitory effect of Tagalsin on murine transplanted tumour and its anti-tumour mechanisms. Methods： Animal models were established by transplanting H22 hepatoma cells to the left oxter of mice, and ten days later they were randomly divided into five groups： blank control group （edible oil）, positive control group （HCFU） and Tagalsin group, including low-dose, middle-dose and high-dose group. All mice were killed 24 h after medication, during which observation was conducted concerning survival conditions, body weight changes, spleen weight and tumor weight of tumor-bearing mice; the spleen index and the tumor inhibitor rate （IR） were calculated and pathological changes of tumor-bearing mice were observed by HE dye. Apoptosis factors p53 and Survivin mRNA were detected by reverse transcription polymerase chain reaction （RT-PCR）. Results： Tagalsin can inhibit hepatoma growth effectively without influencing spleen index and body weight, the tumor inhibitor rate （IR） of low, middle and high dose group of Tagalsin were 15.81%, 36.75% and 74.79% respectively, the tumor inhibitor rate （IR） of HCFU were 73.93%. Apoptosis cells could be found from the specimen of the positive control group and Tagalsin groups. Reverse transcription polymerase chain reaction （RT-PCR） results showed that positive control group’s and Tagalsin treatment groups’ p53 gene expression enhanced significantly and Survivin gene expression dropped comparing with blank group （P 0.05）. Conclusion： Tagalsin can inhibit growth of the H22 hepatoma cells significantly, the mechanism of anti-tumor effect may work by up-regulating p53 expression and down-regulating Survivin expression. Tagalsin may be considered as a potential candidate for chemoprevention.展开更多
Traditionally, the multibasic cleavage site （MBCS） of surface protein H5-hemagglutinin （HA） is converted to a monobasic one so as to weaken the virulence of recombinant H5N1 influenza viruses and to produce inacti...Traditionally, the multibasic cleavage site （MBCS） of surface protein H5-hemagglutinin （HA） is converted to a monobasic one so as to weaken the virulence of recombinant H5N1 influenza viruses and to produce inactivated and live attenuated vaccines. Whether such modification benefits new candidate vaccines has not been adequately investigated. We previously used retroviral vectors to generate wtH5N1 pseudotypes containing the wild-type HA （wtH5） from A/swine/Anhui/ca/2004 （H5N1） virus. Here, we generated mtH5N1 pseudotypes, which contained a mutant-type HA （mtH5） with a modified monobasic cleavage site. Groups of mice were subcutaneously injected with the two types of influenza pseudotypes. Compared to the group immunized with wtH5N1 pseudotypes, the inoculation of mtH5N1 pseudotypes induced significantly higher levels of HA specific IgG and IFN-y in immunized mice, and enhanced protection against the challenge of mouse-adapted avian influenza virus A/Chicken/Henardl2/2004 （H5N1）. This study suggests modification of the H5-hemagglutinin MBCS in retroviral pseudotypes enhances protection efficacy in mice and this information may be helpful for development of vaccines from mammalian cells to fight against H5N 1 influenza viruses.展开更多
Objective: To observe the therapeutic effects of Jingyuankang capsules (精元康胶囊) for leukopenia in AIDS patients. Methods: In this randomized double-blind trial, 58 patients orally took Jingyuankang capsule, analog...Objective: To observe the therapeutic effects of Jingyuankang capsules (精元康胶囊) for leukopenia in AIDS patients. Methods: In this randomized double-blind trial, 58 patients orally took Jingyuankang capsule, analog Leucogen tablet and the HAART (highly active anti-retroviral therapy) drugs, and the other 58 patients took Leucogen tablet, analog Jingyuankang capsule and the HAART drugs all for 6 months, during which the peripheral hemogram was periodically examined to observe the therapeutic effects of Jingyuankang capsule for leukopenia of the AIDS patients. Results: With good therapeutic effect for leukopenia of the AIDS patients, Jingyuankang capsule can enhance leukocyte level as effective as Leucogen tablet in treating grade Ⅰ and grade Ⅱ leukopenia, and more effectively than Leucogen tablet in treating grade Ⅲ leukopenia. No toxic side-effects and adverse reactions were found during the treatment and in the follow-up visit. Conclusion: Jingyuankang capsule can effectively treat leukopenia of the AIDS patients.展开更多
基金Supported by grants from the National "863" Scientific Item (No.2006AA09Z446)Science and Technology of Qingdao (No. 07-2-1-8-NSH-1)
文摘Objective： The aim of our study was to explore the inhibitory effect of Tagalsin on murine transplanted tumour and its anti-tumour mechanisms. Methods： Animal models were established by transplanting H22 hepatoma cells to the left oxter of mice, and ten days later they were randomly divided into five groups： blank control group （edible oil）, positive control group （HCFU） and Tagalsin group, including low-dose, middle-dose and high-dose group. All mice were killed 24 h after medication, during which observation was conducted concerning survival conditions, body weight changes, spleen weight and tumor weight of tumor-bearing mice; the spleen index and the tumor inhibitor rate （IR） were calculated and pathological changes of tumor-bearing mice were observed by HE dye. Apoptosis factors p53 and Survivin mRNA were detected by reverse transcription polymerase chain reaction （RT-PCR）. Results： Tagalsin can inhibit hepatoma growth effectively without influencing spleen index and body weight, the tumor inhibitor rate （IR） of low, middle and high dose group of Tagalsin were 15.81%, 36.75% and 74.79% respectively, the tumor inhibitor rate （IR） of HCFU were 73.93%. Apoptosis cells could be found from the specimen of the positive control group and Tagalsin groups. Reverse transcription polymerase chain reaction （RT-PCR） results showed that positive control group’s and Tagalsin treatment groups’ p53 gene expression enhanced significantly and Survivin gene expression dropped comparing with blank group （P 0.05）. Conclusion： Tagalsin can inhibit growth of the H22 hepatoma cells significantly, the mechanism of anti-tumor effect may work by up-regulating p53 expression and down-regulating Survivin expression. Tagalsin may be considered as a potential candidate for chemoprevention.
基金supported by the National Basic Research Program of China (973: 2012CB518904) from the Ministry of Science and Technology of Chinathe National Natural Science Foundation of China(81201298)
文摘Traditionally, the multibasic cleavage site （MBCS） of surface protein H5-hemagglutinin （HA） is converted to a monobasic one so as to weaken the virulence of recombinant H5N1 influenza viruses and to produce inactivated and live attenuated vaccines. Whether such modification benefits new candidate vaccines has not been adequately investigated. We previously used retroviral vectors to generate wtH5N1 pseudotypes containing the wild-type HA （wtH5） from A/swine/Anhui/ca/2004 （H5N1） virus. Here, we generated mtH5N1 pseudotypes, which contained a mutant-type HA （mtH5） with a modified monobasic cleavage site. Groups of mice were subcutaneously injected with the two types of influenza pseudotypes. Compared to the group immunized with wtH5N1 pseudotypes, the inoculation of mtH5N1 pseudotypes induced significantly higher levels of HA specific IgG and IFN-y in immunized mice, and enhanced protection against the challenge of mouse-adapted avian influenza virus A/Chicken/Henardl2/2004 （H5N1）. This study suggests modification of the H5-hemagglutinin MBCS in retroviral pseudotypes enhances protection efficacy in mice and this information may be helpful for development of vaccines from mammalian cells to fight against H5N 1 influenza viruses.
基金supported by a grant from the National Key Technology R&D Program of the Ministry of Science and Technology of China (No.2004BA719A09-0203)
文摘Objective: To observe the therapeutic effects of Jingyuankang capsules (精元康胶囊) for leukopenia in AIDS patients. Methods: In this randomized double-blind trial, 58 patients orally took Jingyuankang capsule, analog Leucogen tablet and the HAART (highly active anti-retroviral therapy) drugs, and the other 58 patients took Leucogen tablet, analog Jingyuankang capsule and the HAART drugs all for 6 months, during which the peripheral hemogram was periodically examined to observe the therapeutic effects of Jingyuankang capsule for leukopenia of the AIDS patients. Results: With good therapeutic effect for leukopenia of the AIDS patients, Jingyuankang capsule can enhance leukocyte level as effective as Leucogen tablet in treating grade Ⅰ and grade Ⅱ leukopenia, and more effectively than Leucogen tablet in treating grade Ⅲ leukopenia. No toxic side-effects and adverse reactions were found during the treatment and in the follow-up visit. Conclusion: Jingyuankang capsule can effectively treat leukopenia of the AIDS patients.
